Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

First liquid solution for hypertension in cats
Semintra will be launched in a number of EU countries during September 2018.

Easy-to-give solution for pet owners and vets

The first liquid solution for feline hypertension has been launched by Boehringer Ingelheim.

In a press release, Boehringer Ingelheim said that Semintra 10 mg/ml Oral Solution ‘provides a new, well-accepted and easy-to-give liquid formulation, making management of feline hypertension easier for cat owners and veterinarians’.

“We are proud to continue to set new standards of care for cats to optimise their health and well-being through the veterinarian,” said Shawn Hooker, global head of strategic business unit pet vet at Boehringer Ingelheim.

“Early disease detection and early treatment are key to ensure cats live longer and happier lives. With Semintra we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension while providing reliable long-term blood pressure control.”

The approval of Semintra as a veterinary medicine for the treatment of feline systemic hypertension follows marketing authorisation in the EU. It will be launched in a number of countries during September 2018.

Further information about Semintra can be found on the European Medicines Agency website.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'